Xeris Pharmaceuticals | XERS - Current Liabilities


Xeris Pharmaceuticals reported $116.2M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Celltrion KRW 4.01T 343.96B Sep/2025
Cspc Pharmaceutical CNY 10.11B 478.47M Jun/2025
Deva Holding AS TRY 6.43B 1.18B Sep/2023
Dianthus Therapeutics USD 23.86M 3.76M Sep/2025
Divis Laboratories Ltd INR 17.28B 2.76B Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Kangmei Pharma CNY 5.81B 57.93M Sep/2025
Knight Therapeutics CAD 118.15M 12.32M Sep/2024
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 7.82M 1.45M Jun/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Neuren Pharmaceuticals AUD 7.92M 37.84M Jun/2025
Organigram Holdings CAD 126.16M 18.88M Sep/2025
Ovoca Bio EUR 2.44M 1.1M Jun/2022
Pacira USD 107.08M 206.09M Sep/2025
Perrigo USD 1.15B 19.2M Sep/2025
Pharma Mar EUR 88.93M 1.15M Sep/2025
Qiagen NV USD 512.14M 461.26M Dec/2025
Sartorius EUR 1.81B 254.3M Sep/2025
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Supernus Pharmaceuticals USD 330.63M 44.27M Sep/2025
Tilray USD 280.3M 18.13M Mar/2025
Zz Pientze Pharmaceu CNY 2.14B 1.06B Sep/2025